Putaminal dopamine depletion in de novo Parkinson’s disease predicts future development of wearing-off
Objective: The present study aimed to investigate whether the level of presynaptic dopamine neuronal loss predicts future development of wearing-off in de novo Parkinson’s disease.…Neuroinflammation Predicts Dompaminergic Deficit in Early Parkinson Disease: DAT SPECT Imaging Study
Objective: We aimed to investigate whether striatal Dopamine transporter (DaT) uptake could be predicted by Neutrophil to lymphocyte ratio (NLR) or measures of disease severity…Relationship between cognitive dysfunction and striatal uptake of 123I-FP-CIT in patients with Parkinson’s disease
Objective: The objective of this study is to investigate a relationship between cognitive dysfunction and striatal uptake of 123I-FP-CIT SPECT (dopamine transporter (DAT) SPECT) in…Associations of DAT SPECT and TCS with prodromal features of Parkinson’s disease: results in PREDICT-PD participants
Objective: To examine whether changes on dopamine reuptake transporter (DAT) SPECT and transcranial sonography (TCS) correlated with Parkinson’s disease (PD) risk scores and other prodromal…SPECT imaging of striatal DAT availability in Parkinson’s: changes over time and relevance to dyskinesias
Objective: This study was designed to explore in Parkinson’s disease (PD) the role of dopamine transporter (DAT)-specific single photon emission computed tomography (SPECT) imaging as a…Early caudate involvement in Parkinson’s disease may predict future cognitive decline
Objective: 1. To investigate prevalence of caudate dopaminergic dysfunction as measured by 123I-FP-CIT in a large cohort of early stage (< 2 years disease duration)…Global Regulatory Agencies Support the Use of Dopamine Transporter Neuroimaging for Subject Selection in Clinical Trials Targeting Early Stage Parkinson’s Disease – on behalf of Critical Path for Parkinson’s (CPP) Consortium
Objective: A key goal of the Critical Path for Parkinson’s Consortium (CPP) is to qualify, with regulatory agencies, drug development tools for use in PD…Evaluation of regional changes in striatal DAT binding in a progressing Parkinson’s disease (PD) cohort: Lessons for imaging biomarker assessment in disease-modifying therapeutic trials
Objective: To evaluate subregion-dependent striatal changes in dopamine transporter (DAT) binding using 123-I Ioflupane SPECT in PD participants in the Parkinson Progression Marker Initiative (PPMI)…The effects of viral priming on neurotoxin induced neurodegeneration and synapse dysfunction in cell culture models relevant to Parkinson’s disease
Objective: To investigate the effects of viral innate immune activation on neurodegeneration and synaptic protein expression in dopaminergic (DA)-like neurons following treatment with Parkinson's disease…Persistent drug-induced parkinsonism with normal dopamine transporter imaging
Objective: We investigated whether patients with persistent drug-induced parkinsonism (DIP) showing visually normal dopamine transporter (DAT) imaging had minimal changes in striatal DAT activity using…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.